<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1696</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-03-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A Structured Classification and Evaluation of Current and Future Treatments for Systemic Lupus Erythematosus</title>
    <abstract language="eng">Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that has a variety of manifestations and is therefore difficult to find a treatment for. Several advances have occurred in the field of SLE drug discovery, especially since the publishing of the first Genome Wide-Associated Studies in 2005. More than one hundred loci were found to be involved in the disease. Subsequently, the treatments were aimed towards tackling the pathways that were found after the uses of modern genetic techniques. Historically, the FDA approved only two drugs for treatment until the approval of Belimumab in 2011. Ten years later, two more drugs were approved in the same year, with few more drugs expected to receive approval in the near future. This study aims to evaluate the efficacy of these future drugs in addition to the ones considered to be milestones in the treatment of SLE, finding Anifrolumab to be the most promising drug currently on the market for treatment of moderate to severe SLE and Obinutuzumab to be the drug to watch.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16960</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Ahmed Abdelazim</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1696/Abdelazim_Lupus.pdf</file>
  </doc>
  <doc>
    <id>1692</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-27</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-02-14</thesisDateAccepted>
    <title language="eng">MESENCHYMAL STEM CELLS (MSC) IN BREAST CANCER TREATMENT: ADVANTAGES AND CHALLENGES OVER TRADITIONAL THERAPIES</title>
    <abstract language="eng">Breast cancer is one of the most prevalent and deadly malignancies in women globally, due to its aggressive behavior and poor response to traditional treatments. Despite the significant improvements in understanding of tumor therapies, efforts to treat patients with advanced cancer are still hampered by the size and heterogeneity of the tumor burden and the development of drug resistance. Therefore, the need for novel therapeutic strategies is essential.&#13;
Mesenchymal stem cells (MSCs) have been studied for a long time with encouraging results in the treatment of metastatic cancers, including breast cancer. The discovery of MSCs' therapeutic abilities to inhibit the growth of cancer, cause cell death, and trigger immune responses served as a catalyst for the development of bioengineered MSCs. The use of MSCs in cell therapy is the subject of numerous investigations now. &#13;
This thesis aimed to summarize the current knowledge on traditional breast cancer treatments and compare them to novel approaches based on MSCs usage. To this end, scientific publications retrieved from databases such as PubMed were selected considering specific inclusion/exclusion criteria and were extensively analyzed. Results obtained underline the potential applications of MSCs for breast cancer treatment, such as using MSCs as carriers of oncolytic viruses, suicide genes, and anticancer medicines to malignancies. Furthermore, challenges and limitations of several MSCs based treatments and MSCs control were evaluated and discussed based on ongoing clinical trials.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16927</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Olga Chentsova</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>MSC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Mesenchymal stem cells</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Traditional cancer therapies breast cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>BC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Treatment</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1692/Chentsova_MSCs.pdf</file>
  </doc>
</export-example>
